Mustang Bio
Logotype for Mustang Bio Inc

Mustang Bio (MBIO) investor relations material

Mustang Bio Q3 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Mustang Bio Inc
Q3 2026 earnings summary5 Nov, 2026

Executive summary

  • Q3 2026 net loss was $964K, versus $468K in Q3 2025; cash and equivalents were $14.3M at September 30, 2026.

  • Development remains focused on MB-101 CAR T and MB-108 oncolytic virus for solid tumors; a potential MB-109 investigator-sponsored study is being prepared for Q1 2027.

  • Cash is expected to fund operations for at least 12 months from the filing date, while continued losses and future financing needs remain significant.

Financial highlights

  • Q3 2026 operating expenses were $1.058M, versus $624K in Q3 2025; operating loss was $1.058M, versus $624K.

  • Q3 2026 R&D expense was $208K, compared with a $333K credit in Q3 2025; excluding the prior-year $500K aged-payables settlement benefit, the comparison reflects higher R&D spending.

  • Q3 2026 G&A expense was $850K, down from $957K; lower prior-year Fortress financing-related equity fees partly offset higher personnel costs.

  • 9M 2026 net loss was $2.991M, versus $1.383M; operating expenses were $3.286M, versus $1.762M.

  • No product revenue has been generated; accumulated deficit reached $401.6M at September 30, 2026.

Outlook and guidance

  • Cash and equivalents of $14.3M are expected to fund operations for at least 12 months from the filing date; continued operating losses and negative operating cash flow are expected.

  • R&D costs are expected to increase with initiation of the MB-109 investigator-sponsored study at City of Hope.

  • MB-109 trial initiation could occur in Q1 2027; stability testing for MB-108 clinical material is expected ahead of a potential IND allowance and trial start.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Mustang Bio earnings date

Logotype for Mustang Bio Inc
Q4 202622 Mar, 2027
Mustang Bio
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Mustang Bio earnings date

Logotype for Mustang Bio Inc
Q4 202622 Mar, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Mustang Bio, Inc. is a biotechnology company focused on the development of cell and gene therapies for the treatment of cancer and rare genetic diseases. The company specializes in advancing innovative approaches such as chimeric antigen receptor (CAR) T-cell therapies and gene editing technologies. The company is headquartered in Worcester, Massachusetts, and its shares are listed on the NASDAQ.